Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (115)

« Back to Publications

Maternal views on RSV vaccination in the UK's second season.

O'Hagan S. et al, (2026), Lancet Infect Dis, 26, e209 - e211

Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trials.

Bijukchhe SM. et al, (2026), Lancet Infect Dis

The effect of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine on nasopharyngeal colonisation following human infection challenge with serotype 3 and serotype 6B (PREVENTING PNEUMO 2): a double-masked, randomised, controlled, phase 4 trial.

Liatsikos K. et al, (2026), Lancet Microbe, 7

Predicting Salmonella Typhi incidence using prevalence metrics from sentinel studies of community-onset bloodstream infections

Hagedoorn N. et al, (2026)

SARS-CoV-2-Specific Immune Responses to Vaccination in Children and Adolescents with Suppressed Immune Systems: A Prospective, Observational Study.

Brugha R. et al, (2026), J Pediatr, 289

Phase II multicentre double-blind randomised controlled trial of a Bivalent VaccInation against Salmonella Typhi and Paratyphi A (BiVISTA) using a controlled human infection model of paratyphoid A infection: study protocol.

Paganotti Vicentine M. et al, (2026), BMJ Open, 16

Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial.

Kelly E. et al, (2026), J Infect, 92

Persistence of Immune Responses 5 Years After Vaccination With a Single Dose of Typhoid Conjugate Vaccine (TCV) in Nepalese Children

Pant D. et al, (2026)

Eight-Year Vaccine Protection Following a Single Dose of VI-Tetanus Toxoid Conjugate Vaccine in Nepali Children: Extended Follow-Up of the TyVAC Nepal Randomised Controlled Trial

Pant D. et al, (2026)

Impact of Dosing Interval on Immunogenicity Following a Heterologous Typhoid Conjugate Vaccine Booster in Nepalese Children: An Observational Study

Zhang Y. et al, (2026)

Bivalent Prefusion F Vaccination in Pregnancy and Protection Against Respiratory Syncytial Virus Hospitalisation in Infants Until the Age of Six Months: Assessment of a United Kingdom-Wide National Vaccination Programme

O'Hagan S. et al, (2026)

Modeling Indirect Protection from Typhoid Conjugate Vaccines in the TyVAC-Bangladesh Trial

Walker J. et al, (2025)

Protocol for a phase IV, Experimental Human Pneumococcal Challenge (EHPC) model to investigate Streptococcus pneumoniae serotype 3 (SPN3) colonisation following PCV15, a double-blind randomised controlled trial in healthy participants aged 18-50 years in the UK (RATIONALE-15).

Macedo BRD. et al, (2025), BMJ Open, 15

Safety, Efficacy, and Immunogenicity of a Salmonella Paratyphi A Vaccine.

McCann N. et al, (2025), N Engl J Med, 393, 1704 - 1714

Comparative Epidemiology of Salmonella enterica Serovers Paratyphi A and Typhi Causing Enteric Fever, Bangladesh, 2018-2020.

Rahman SIA. et al, (2025), Emerg Infect Dis, 31, 1922 - 1934

Load More

1
2
3
4
5
6
7
...
»